Results 141 to 150 of about 61,468 (247)

Characterization of Phosphorylation Status and Kinase Activity of Src Family Kinases Expressed in Cell-Based and Cell-Free Protein Expression Systems. [PDF]

Biomolecules, 2021
Kinoshita-Kikuta E, Kinoshita E, Suga M, Higashida M, Yamane Y, Nakamura T, Koike T.   +6 more
europepmc   +1 more source

SRC Family Tyrosine Kinase [PDF]

, 2020
openaire   +1 more source

Inhibition of leucine‐rich kinase 2 (LRRK2) promotes peripheral axon regeneration via phosphorylation‐network remodelling

British Journal of Pharmacology, EarlyView.
Background and Purpose In contrast to neurons in the central nervous system, neurons in the peripheral nervous system can regenerate axons after injury via activation of a pro‐regenerative transcriptional programme. Pathogenic mutations in leucine‐rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease, and several small ...
Eun‐Hae Jang, Eun Mo Yang, Gil Song, Seung Min Park, Harryn Choi, Jaeyong Kim, Chanil Kim, Yunho Gim, Hyuk‐Joo Jeon, Yewon Cho, Jong Bae Park, Eun‐Mi Hur   +11 more
wiley   +1 more source

Csk-dependent and -independent control of Src family kinases directs neuronal migration in the developing cerebral cortex. [PDF]

J Biol Chem
Nishimura YV, Ito S, Kawauchi T.
europepmc   +1 more source

Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain. [PDF]

Curr Neuropharmacol, 2021
Nie L, Ye WR, Chen S, Chirchiglia D, Wang M.   +4 more
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Correction: Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. [PDF]

Cell Mol Life Sci
Yu GT, Mao L, Wu L, Deng WW, Bu LL, Liu JF, Chen L, Yang LL, Wu H, Zhang WF, Sun ZJ.   +10 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Dual Inhibition of SRC Family Kinases and Sorafenib Enhances Anti-Tumor Activity in Hepatocellular Carcinoma Cells. [PDF]

Int J Mol Sci
Cabral LK, Disoma C, Tarchi P, El-Khobar KE, Agustiningsih A, Dituri F, Tiribelli C, Sukowati C.   +7 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source